【レポートの概要（一部）】
Table of Contents
Chapter 1. Executive Summary
1.1. Pharmacovigilance– Industry Summary and Critical Success Factors (CSFs)
Chapter 2. Pharmacovigilance Industry Outlook
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Pharmacovigilance – Market dynamics
2.3.1. Market Driver Analysis
2.3.2. Market Restraint Analysis
2.4. Key Opportunities Prioritized
2.5. Pharmacovigilance – PESTEL Analysis
2.6. Pharmacovigilance Company Market Share Analysis, 2013
Chapter 3. Pharmacovigilance Clinical Trial Phase Outlook
3.1. Pharmacovigilance market share, by clinical trial phase, 2013 & 2020
3.2. Preclinical
3.2.1. Preclinical Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.3. Phase 0
3.3.1. Phase 0 Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.4. Phase I
3.4.1. Phase I Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.5. Phase II
3.5.1. Phase II Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.6. Phase III
3.6.1. Phase III Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.7. Phase IV
3.7.1. Phase IV Market Estimates and Forecasts, 2012 – 2020 (USD Million)
Chapter 4. Pharmacovigilance Type of Service Provider Outlook
4.1. Pharmacovigilance market share, by type of service provider, 2013 & 2020
4.2. In- House
4.2.1. In-House Market Estimates and Forecasts, 2012 – 2020 (USD Million)
4.3. Contract Outsourcing
4.3.1. Contract Outsourcing Market Estimates and Forecasts, 2012 – 2020 (USD Million)
Chapter 5. Pharmacovigilance Regional Outlook
5.1. Pharmacovigilance market share by region, 2012 & 2020
5.2. North America
5.2.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.2.2. Market Estimates and Forecasts, by Type of Service Provider
5.3. Europe
5.3.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.3.2. Market Estimates and Forecasts, by Type of Service Provider
5.4. Asia Pacific
5.4.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.4.2. Market Estimates and Forecasts, by Type of Service Provider
5.5. RoW
5.5.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.5.2. Market Estimates and Forecasts, by Type of Service Provider
Chapter 6. Competitive Landscape
6.1 Accenture Plc.
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Product Benchmarking
6.1.4 Strategic Initiatives
6.2 Boehringer Ingelheim GmbH
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Product Benchmarking
6.2.4 Strategic Initiatives
6.3 Bristol-Myers Squibb
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Product Benchmarking
6.3.4 Strategic Initiatives
6.4 Clinquest Group B.V.
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Product Benchmarking
6.4.4 Strategic Initiatives
6.5 Cognizant Technology Solutions Corporation
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Product Benchmarking
6.5.4 Strategic Initiatives
6.6 Covance, Inc.
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Product Benchmarking
6.6.4 Strategic Initiatives
6.7 F. Hoffmann-La Roche Ltd
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Product Benchmarking
6.7.4 Strategic Initiatives
6.8 GlaxoSmithKline (GSK)
6.8.1 Company Overview
6.8.2 Financial Performance
6.8.3 Product Benchmarking
6.8.4 Strategic Initiatives
6.9 IBM Corporation
6.9.1 Company Overview
6.9.2 Financial Performance
6.9.3 Product Benchmarking
6.9.4 Strategic Initiatives
6.10 ICON, Plc
6.10.1 Company Overview
6.10.2 Financial Performance
6.10.3 Product Benchmarking
6.10.4 Strategic Initiatives
6.11 iGATE Corporation
6.11.1 Company Overview
6.11.2 Financial Performance
6.11.3 Product Benchmarking
6.11.4 Strategic Initiatives
6.12 iMEDGlobal Corporation
6.12.1 Company Overview
6.12.2 Financial Performance
6.12.3 Product Benchmarking
6.12.4 Strategic Initiatives
6.13 Infosys
6.13.1 Company Overview
6.13.2 Financial Performance
6.13.3 Product Benchmarking
6.13.4 Strategic Initiatives
6.14 Ipca Laboratories Ltd
6.14.1 Company Overview
6.14.2 Financial Performance
6.14.3 Product Benchmarking
6.14.4 Strategic Initiatives
6.15 Janssen Research & Development, LLC
6.15.1 Company Overview
6.15.2 Financial Performance
6.15.3 Product Benchmarking
6.15.4 Strategic Initiatives
6.16 Novartis International AG
6.16.1 Company Overview
6.16.2 Financial Performance
6.16.3 Product Benchmarking
6.16.4 Strategic Initiatives
6.17 PAREXEL International Corporation
6.17.1 Company Overview
6.17.2 Financial Performance
6.17.3 Product Benchmarking
6.17.4 Strategic Initiatives
6.18 Pfizer, Inc.
6.18.1 Company Overview
6.18.2 Financial Performance
6.18.3 Product Benchmarking
6.18.4 Strategic Initiatives
6.19 Pharmaceutical Product Development, Inc. (PPD, Inc.)
6.19.1 Company Overview
6.19.2 Financial Performance
6.19.3 Product Benchmarking
6.19.4 Strategic Initiatives
6.20 Sanofi Aventis
6.20.1 Company Overview
6.20.2 Financial Performance
6.20.3 Product Benchmarking
6.20.4 Strategic Initiatives
6.21 Synowlwedge LLC
6.21.1 Company Overview
6.21.2 Financial Performance
6.21.3 Product Benchmarking
6.21.4 Strategic Initiatives
6.22 Wipro Ltd.
6.22.1 Company Overview
6.22.2 Financial Performance
6.22.3 Product Benchmarking
6.22.4 Strategic Initiatives
6.23 PRA Health Sciences Inc.
6.23.1 Company Overview
6.23.2 Financial Performance
6.23.3 Product Benchmarking
6.23.4 Strategic Initiatives
6.24 Quantum Solutions India
6.24.1 Company Overview
6.24.2 Financial Performance
6.24.3 Product Benchmarking
6.24.4 Strategic Initiatives
6.25 Quintiles Transnational Corporation
6.25.1 Company Overview
6.25.2 Financial Performance
6.25.3 Product Benchmarking
6.25.4 Strategic Initiatives
6.26 inVentiv Health Inc.
6.26.1 Company Overview
6.26.2 Financial Performance
6.26.3 Product Benchmarking
6.26.4 Strategic Initiatives
6.27 OptumInsight, Inc.
6.27.1 Company Overview
6.27.2 Financial Performance
6.27.3 Product Benchmarking
6.27.4 Strategic Initiatives
6.28 United BioSource Corporation
6.28.1 Company Overview
6.28.2 Financial Performance
6.28.3 Product Benchmarking
6.28.4 Strategic Initiatives
6.29 Ecron Acunova
6.29.1 Company Overview
6.29.2 Financial Performance
6.29.3 Product Benchmarking
6.29.4 Strategic Initiatives
6.30 Fortitude Clinical
6.30.1 Company Overview
6.30.2 Financial Performance
6.30.3 Product Benchmarking
6.30.4 Strategic Initiatives
6.31 ITClinical
6.31.1 Company Overview
6.31.2 Financial Performance
6.31.3 Product Benchmarking
6.31.4 Strategic Initiatives
Chapter 7. Methodology and Scope
7.1. Research Methodology
7.2. Research Scope & Assumption
7.3. List of Data Sources
List of Tables
1. Pharmacovigilance Market – Industry Summary & Critical Success Factors (CSFs)
2. Global Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020, Revenue (USD Million)
3. Global Pharmacovigilance Market Revenue, By Type of Service Provider , 2012 – 2020, Revenue (USD Million)
4. Global Pharmacovigilance Market Revenue, By Region, 2012 – 2020, Revenue (USD Million)
5. Pharmacovigilance Market – Key market driver analysis
6. Pharmacovigilance – Key market restraint analysis
7. North America Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
8. North America Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
9. North America Pharmacovigilance Market Revenue, By Type of Service provider, 2012 – 2020 (USD Million)
10. Europe Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
11. Europe Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
12. Europe Pharmacovigilance Market Revenue, By Type of service Provider, 2012 – 2020 (USD Million)
13. Asia Pacific Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
14. Asia Pacific Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
15. Asia Pacific Pharmacovigilance Market Revenue, By Type of service Provider, 2012 – 2020 (USD Million)
16. RoW Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
17. RoW Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
18. RoW Pharmacovigilance Market Revenue, By Type of Service Provider, 2012 – 2020 (USD Million)
List of Figures
1. Pharmacovigilance: Market Segmentation
2. Global Pharmacovigilance Market, 2012 – 2020, Revenue (USD Million)
3. Pharmacovigilance Market Dynamics
4. Key Opportunities Prioritized
5. Pharmacovigilance Market – Porter’s Analysis
6. Pharmacovigilance Market – PESTEL Analysis
7. Pharmacovigilance Company Market Share Analysis, 2013
8. Pharmacovigilance Market Share, By Clinical Trial Phase, 2013 & 2020
9. Pharmacovigilance Market Share, By Type of Service Provider, 2013 & 2020
10. Pharmacovigilance Market Share, By Region, 2013 & 2020
【レポート販売概要】
■ タイトル：医薬品の副作用調査の世界市場分析：臨床試験フェーズ別（前臨床試験、フェーズI / 1、フェーズII / 2、フェーズIII / 3、フェーズIV / 4試験）、サービス提供者別（自宅内、契約委託）、セグメント予測、-2020■ 英文：Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020
■ 発行日：2015年2月15日
■ 調査会社：Grand View Research
■ 商品コード：GVIEW707656
■ 調査対象地域：グローバル
- アンドロイド搭載のスマートフォン及びタブレット市場（モデル別、デザイン別、地域別）2012年第2四半期（Android Smartphones & Tablets Installed Base by Device Model, Form Factor & Region Q2'2012）Covering over 600 Tablets and Smartphones from 63 vendors, this XLS database tracks Android activations by individual device model, form factor, vendor and region. The target audience for this report includes handset manufacturers, application developers and mobile network operators. All variants of particular device series are individually covered in the database. As an example, for the Samsung G …
- 世界のバイオシミラー（バイオ後続品）市場動向：エリトロポエチン、ヒト成長ホルモン、果粒球コロニー刺激因子、モノクローナル抗体などThe much awaited biosimilars have finally entered the US pharmaceutical market with the FDA approval of Sandoz’s Zarxio, a G-CSF. The move is being hailed by biosimilar manufacturers and is expected to fuel numerous submissions in the coming days, making US a significant region for biosimilar activity. At the same time, as shrinking budgets are rooting for reduced healthcare expenditures and major …
- 世界のSAMOLED（スーパー有機EL）市場2015The Global Super Active-Matrix Organic Light-Emitting Diode (SAMOLED) Industry Report 2015 is a professional and in-depth study on the current state of the Super Active-Matrix Organic Light-Emitting Diode (SAMOLED) industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Super Active-Matrix Organic Light-Em …
- 坐骨神経痛治療のグローバル臨床試験動向（2014年下半期）Sciatic Pain Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Sciatic Pain Global Clinical Trials Review, H2, 2014" provides data on the Sciatic Pain clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sciatic Pain. It includes an overview of the trial numbers and their recruitment status as per the sit …
- 世界のエラストマー塗料市場2015The Global Elastomeric Coating Industry Report 2015 is a professional and in-depth study on the current state of the Elastomeric Coating industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Elastomeric Coating market analysis is provided for the international markets including development trends, compet …
- 世界のモバイル音楽アクセサリー市場動向（2012-2016）TechNavio's analysts forecast the Global Mobile Music Accessories market to grow at a CAGR of 12.55 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing number of technological advancement and innovations. The Global Mobile Music Accessories market has also been witnessing partnerships between mobile device manufacturers and music accessori …
- Gilotrif (Non-Small Cell Lung Cancer)：市場予測と分析（～2022）Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment lan …
- SDN、NFV、ネットワーク仮想化バイブル2014-2020（The SDN, NFV & Network Virtualization Bible: 2014～2020）While the benefits of Software Defined Networking (SDN) and network virtualization are well known in the enterprise IT and data center world, both technologies also bring a hosts of benefits to the telecommunications service provider/carrier community. Not only can SDN and network virtualization help address the explosive capacity demand of mobile traffic, but they can also reduce the CapEx and Op …
- Strike Energy Limited：石油・ガスの開発・生産動向及びコスト分析– 2012Strike Energy Limited Oil & Gas Exploration and Production Operations and Cost Analysis – 2012 Summary Strike Energy Limited Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
- 自転車用クランクモーターの世界市場2016-2020About Bicycle Crank Motor A crank motor, also called a mid-drive motor or a central motor, is a centralized motor that is placed inside the seat tube of a cycle. It is connected to the crankshaft through interlocking gears. The gear at the bottom of the motor locks into the gear ring, which is placed on top of the crankshaft. Technavio’s analysts forecast the global bicycle crank motor market to g …
- 世界の抗嘔吐薬市場：嘔吐・抗嘔吐薬、5-HT3拮抗薬、カンナビノイド薬、ドーパミン拮抗薬Treatments for nausea and vomiting – explore business trends, R&D, and revenue forecasts What’s the future of treating nausea and vomiting? For those medicines you get sales predictions, also exploring research and development. Those treatments hold high potential. There you assess results, progress, therapies, and opportunities. Visiongain’s new report forecasts those revenues to 2024 at overall …
- FieldPoint Petroleum Corporation：石油・ガスの開発・生産動向及びコスト分析- Q1, 2013FieldPoint Petroleum Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary FieldPoint Petroleum Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report …
- デンタルフロスの世界市場2017-2021About Dental FlossDental floss is essentially a thread, which removes food trapped between teeth and removes the film of bacteria that forms there before it has a chance to harden into plaque. Toothbrush bristles alone cannot clean effectively between these tight spaces and hence, the need for dental floss arises. Technavio’s analysts forecast the global dental floss market to grow at a CAGR of 5. …
- 手術用動力器具の世界市場2016-2020About Surgical Power Tools Surgical power tools are specially manufactured devices that utilize different sources of energy for carrying out a particular action such as drilling or fixing implants during surgeries. Many surgical power tools such as drills, saws, and reamers are available in the market. These devices use different energy sources such as electricity, battery, or compressed gases lik …
- 医薬品受託包装の世界市場2019-2023About this market Growing demand for sustainable packaging to drive market growth. The growing environmental concerns are increasing the demand for sustainable packaging solutions among the pharmaceutical manufacturers. Plastic films and plastic materials are mostly derived from petroleum feedstock. Their adverse effects on the environment have encouraged the vendors to provide eco-friendly packag …
